aWashington University School of Medicine, St Louis, MO;

bHarvard T. H. Chan School of Public Health, Boston, MA; and

cUniversity of Colorado Denver-Anschutz Medical Campus, Aurora, CO.

Correspondence to: Jane O'Halloran, MD, Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 620 S Taylor Ave, St. Louis, MO 63110 (e-mail: [email protected]).

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

K.M.E. reports institutional research funding from for Gilead and consultancy for Merck, Gilead, and ViiV. All other authors report no potential conflicts of interest.